Citigroup Inc. Cuts Stake in Elanco Animal Health Incorporated $ELAN

Citigroup Inc. reduced its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 75.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,058 shares of the company’s stock after selling 344,563 shares during the quarter. Citigroup Inc.’s holdings in Elanco Animal Health were worth $2,257,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. SJS Investment Consulting Inc. increased its position in Elanco Animal Health by 2,563.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares during the period. Fifth Third Bancorp boosted its stake in shares of Elanco Animal Health by 3,018.3% during the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after purchasing an additional 2,807 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in shares of Elanco Animal Health by 184.3% during the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after purchasing an additional 2,414 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average cost of $21.30 per share, with a total value of $213,000.00. Following the transaction, the director directly owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. This represents a 8.21% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey N. Simmons purchased 22,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $21.75 per share, with a total value of $478,500.00. Following the completion of the purchase, the chief executive officer owned 167,000 shares of the company’s stock, valued at $3,632,250. The trade was a 15.17% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 43,450 shares of company stock worth $937,883 over the last quarter. Company insiders own 0.89% of the company’s stock.

Elanco Animal Health Trading Down 2.3%

NYSE ELAN opened at $23.38 on Friday. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $27.72. The company has a 50 day moving average price of $24.45 and a 200 day moving average price of $22.02. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. The firm has a market cap of $11.62 billion, a PE ratio of -48.71, a price-to-earnings-growth ratio of 2.97 and a beta of 1.83.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the firm earned $0.14 earnings per share. Elanco Animal Health’s revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. KeyCorp increased their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Wednesday, November 19th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. Finally, Leerink Partners upped their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.67.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.